Plasma tau and neurodegenerative markers as predictors of rate of AD progression

血浆 tau 蛋白和神经退行性标记物作为 AD 进展率的预测因子

• 批准号: 10491047
• 负责人: JASMEER P CHHATWAL
• 金额: $ 84.82万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-30 至 2026-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10491047
• 关键词: Affect; Alzheimer' s Disease; Alzheimer' s disease diagnosis; Alzheimer' s disease pathology; Alzheimer' s disease related dementia; Alzheimer’s disease biomarker; American; Amyloid; Biological Markers; Blood; Clinic; Clinical; Clinical Research; Cognition; Cognitive; Cross-Sectional Studies; Data; Dementia; Diagnosis; Disease Progression; Family; Family Caregiver; Family health status; Funding; Healthcare; Healthcare Systems; Hippocampus (Brain); Image; Immunoassay; Impaired cognition; Impairment; Light; Magnetic Resonance Imaging; Measures; Medical; Memory Loss; Modeling; N-terminal; Nerve Degeneration; Neurology; Participant; Pathologic; Pathology; Patients; Performance; Persons; Plasma; Population; Positron-Emission Tomography; Public Health; Research Personnel; Risk; Sampling; Signal Transduction; Spinal Puncture; Standardization; Syndrome; Time; Uncertainty; amyloid precursor protein processing; base; blood-based biomarker; clinical care; clinical diagnosis; clinical diagnostics; clinical predictors; cognitive performance; cost; design; diagnostic tool; flexibility; formycin triphosphate; functional decline; gamma secretase; imaging biomarker; improved; in vivo; neurofilament; neuroimaging; novel; predictive marker; prognostic model; prospective; relative cost; research study; risk stratification; tau Proteins; tau aggregation; tau-1; tool; β-amyloid burden

Project Abstract: Alzheimer's disease and related dementias (ADRD) affect tens of millions of people around the world and represent a staggering challenge for patients, families, and healthcare systems. For some who present with mild levels of cognitive impairment, there is rapid worsening of cognition and function, whereas for others, the rate of progression can be absent or much slower. Understanding this variability in rate of progression is critically important to patients, families, and clinical researchers alike, and is not well-predicted by common, clinically available biomarker tools. Blood-based markers of AD pathology and neurodegeneration have potential for widespread use in clinical research and even clinical care, due to their non-invasiveness, cost relative to neuroimaging, and lack of medical contraindications to limit their use. Here we examine a set of newly developed, blood-based AD biomarkers (including neurofilament light chain, phospho-tau species, tau, and Ab fragments) that may fill this gap. Leveraging prospectively acquired samples from a large clinic population and from local clinical research studies, we will determine how these plasma measures relate to variable rates of "real-world" cognitive and functional decline, as well as to imaging-based measures of neurodegeneration and AD pathologic progression.

项目摘要： 阿尔茨海默病和相关痴呆症(ADRD)影响着全球数千万人， 对于患者、家庭和医疗保健系统来说，这是一个惊人的挑战。对于一些在场的人来说 轻度认知障碍，认知和功能迅速恶化，而对于其他人， 进展的速度可以是没有的，也可以慢得多。理解进步率的这种变异性是 对患者、家属和临床研究人员都至关重要，而且通常不能很好地预测， 临床上可用的生物标志物工具。AD病理和神经退行性变的血液标记物 由于它们的非侵入性、成本，因此有可能在临床研究甚至临床护理中广泛使用 相对于神经成像，以及缺乏医学禁忌症来限制其使用。在这里，我们研究了一组 新开发的基于血液的AD生物标记物(包括神经丝轻链、磷酸化tau、tau、 和抗体片段)，可以填补这一空白。利用从大型诊所获得的预期样本 根据当地的临床研究，我们将确定这些血浆指标如何与 “真实世界”认知和功能衰退的不同比率，以及基于成像的测量 神经退行性变与AD病理进展。